Ultragenyx Pharmaceutical RARE reported first-quarter 2025 loss of $1.57 per share, wider than the Zacks Consensus Estimate ...

The S&P 500 ceded 0.6%, as the benchmark index held above its 50-day moving average. The S&P 500 also snapped a nine-day ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

Sure, stocks may not have hit their ultimate bottom just yet. They're arguably closer to it than not, though. And five years ...

BioCryst Pharma's ORLADEYO leads HAE market growth, with strong financial performance and potential despite rising ...

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ...

Derivatives exchange Cboe Global Markets reported a record first-quarter profit on Friday and boosted its annual revenue ...

Having significant capital in the bank when investing in equities is helpful, but is by no means necessary. If you're patient ...

today announces the in-licensing of two clinical-stage oncology programs from Astex Pharmaceuticals (‘Astex’), a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd. Mosaic has identified ...

With countless CBD brands on the market today, you may be wondering where to begin. We did the research so you can make an informed decision. Here, we share our picks of the top CBD brands in ...

Credit: HJBC / Shutterstock. On 16 April 2025, the European Commission (EC) published a press release announcing the launch of and details regarding the first two medicinal products to undergo joint ...